PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Tumor-only genetic sequencing may misguide cancer treatment in nearly half of all patients

Johns Hopkins scientists say the genetic code of tumors must be compared to patients' noncancer genome to get a true picture

2015-04-15
(Press-News.org) A study by Johns Hopkins scientists strongly suggests that sequencing tumor genomes for clues to genetic changes might misdirect treatment in nearly half of all patients unless it is compared first to a genetic readout of their noncancerous tissue.

The investigators at the Johns Hopkins Kimmel Cancer Center say their analysis of more than 800 cancer patients' sequencing data, which was generated by Personal Genome Diagnostics Inc., a company co-founded by the researchers, shows that without such comparisons, attempts to individualize cancer therapy may be inappropriate in certain cases, and patients may get the wrong targeted therapies.

A report on the work appears in the April 16 issue of Science Translational Medicine.

"Increasingly, hospitals and companies are beginning to sequence patients' tumors in an attempt to personalize therapy. However, many are not sequencing each person's normal tissue to filter out noncancer-related changes and to really understand what is occurring in the tumor," says Victor Velculescu, M.D., Ph.D., a professor of oncology and pathology and co-director of the Cancer Biology Program at the Johns Hopkins University School of Medicine.

Velculescu explains that personalized therapies increasingly designed to target the unique genetic changes that drive a person's tumor depend on accurate assessment of a tumor genome, but not all genetic changes in a cancer are directly related to the cancer. Some, he explains, are so-called germline changes, which are inherited changes in genes that are in normal tissues and differ from person to person.

"We all carry variations in our germline genome. They're part of what makes us individually unique," says Valsamo Anagnostou, M.D., Ph.D., a clinical fellow at the Johns Hopkins University School of Medicine and co-author of the study. Only by comparing the genetic sequence of an individual's tumor and his or her own normal cells can clinicians know which changes are more likely to be cancer-related and which treatments are likely to work.

Treatment decisions based on faulty genetic information might affect "any patient whose genome is being sequenced right now and could amount to thousands of patients in the near future" as genetic testing of tumors becomes more common, Anagnostou says. Inaccurate genetic information can lead to serious side effects from inappropriate therapies, lack of useful targeted therapies and increased costs of patient care from misguided medicines.

For the study, Velculescu and his colleagues compared the genomes of tumor and normal tissue from 815 patients who had a variety of cancers, including breast, brain, renal, gastric, lung, pancreatic, blood cancers and melanoma.

When the researchers only looked at the genetic changes found in a patient's tumor and filtered out the most well-known germline changes, they counted 382 possible tumor-related changes. But after comparing a patient's full germline genome to his or her tumor genomes, they determined that, on average, 249 of these changes were part of the patient's normal, inherited genetic variation and were not tumor-specific.

In other words, Velculescu says, 65 percent of the genetic changes identified with tumor-only genetic sequencing were "false positives" and not related to the patient's cancer.

The researchers also looked at changes in "actionable genes," or genes for which some kind of drug or cancer therapy has already been identified. When they looked for these changes in the tumor alone, they identified on average 2.4 changes per patient. However, they found that 33 percent of those changes were also false positives when they compared the tumor genome to the patient's germline genome. These false positives affected 48 percent of the patients analyzed.

"In tumor-only analyses, we found that nearly half of patients had tumor mutations that were actually germline or false positives in actionable genes, and they could lead to inappropriate therapy," Velculescu says.

Velculescu and his team acknowledge there may be challenges in implementing tumor-normal analyses in a clinical setting. These include the additional work and costs of sequencing and analyzing a patient's normal tissue along with his or her tumor tissue but Velculescu says some efficiencies could be realized by using the patient's saliva, blood or normal tissue recovered during a biopsy or tumor removal. Costs for tumor gene sequencing begin at several thousand dollars, which would increase if sequencing was done on DNA from normal tissue as well. Velculescu also notes that health insurance may not fully cover normal-tissue genetic sequencing. Addressing concerns about patient privacy when normal genomes are sequenced, Velculescu says that comparisons of tumor and normal sequences can be designed to use germline changes as a filter without identifying what those germline changes are and what their potential health implications might be.

In addition to selecting personalized therapies for patients with cancer, sequencing the normal tissue genome can also increase the overall understanding of cancer, including finding cancer predisposition due to germline genome changes, says Velculescu. In this study, the germline analyses identified changes in cancer-related genes in 3 percent of the patients who had no known signs of genetically linked cancer. "These analyses can help us find alterations in cancer-predisposing genes in ways that weren't previously appreciated," he suggests.

INFORMATION:

Other Johns Hopkins and Personal Genome Diagnostics scientists who contributed to the research include Siân Jones, Karli Lytle, Sonya Parpart-Li, Monica Nesselbush, David R. Riley, Manish Shukla, Bryan Chesnick, Maura Kadan, Eniko Papp, Kevin G. Galens, Derek Murphy, Theresa Zhang, Lisa Kann, Mark Sausen, Samuel V. Angiuoli and Luis A. Diaz Jr.

Funding for the study was provided in part by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the Commonwealth Foundation, the American Association for Cancer Research's Stand Up To Cancer-Dream Team Translational Cancer Research Grant, the John G. Ballenger Trust, a FasterCures Research Acceleration Award, Swim Across America and the National Institutes of Health (CA121113).

Victor Velculescu and Luis Diaz Jr. are co-founders of Personal Genome Diagnostics and are members of its scientific advisory board and board of directors. They own Personal Genome Diagnostics stock, which is subject to certain restrictions under university policy. The terms of these arrangements are managed by The Johns Hopkins University in accordance with its conflict-of-interest policies.

Johns Hopkins Kimmel Cancer Center
Office of Public Affairs
Media Contacts:
Vanessa Wasta, 410-614-2916, wasta@jhmi.edu
Amy Mone, 410-614-2915, amone@jhmi.edu



ELSE PRESS RELEASES FROM THIS DATE:

Patents forecast technological change

2015-04-15
How fast is online learning evolving? Are wind turbines a promising investment? And how long before a cheap hoverboard makes it to market? Attempting to answer such questions requires knowing something about the rate at which a technology is improving. Now engineers at MIT have devised a formula for estimating how fast a technology is advancing, based on information gleaned from relevant patents. The researchers determined the improvement rates of 28 different technologies, including solar photovoltaics, 3-D printing, fuel-cell technology, and genome sequencing. They ...

Big data key to precision medicine's success

2015-04-15
NEW YORK (April 15, 2015) -- Technological advances are enabling scientists to sequence the genomes of cancer tumors, revealing a detailed portrait of genetic mutations that drive these diseases. But genomic studies are only one piece of the puzzle that is precision medicine, a Weill Cornell Medical College researcher writes in Nature. In order to realize the promise of this field, there needs to be an increased focus on creating robust clinical databases that include medical histories from patients around the country, which physicians can then use along with genomic data ...

Wind bursts strongly affect El Niño severity

2015-04-15
The long-forecasted El Niño event of 2014/15 did not meet expectations. On March 5, 2015, the National Weather Service finally declared a "weak" event arriving several months later than expected, formally dashing predictions that we would see a major event on par with the monster El Niño of 1997/98 that would bring much-needed rain to California and other western states. Now, a team of researchers believes that they know why this year's event--and others like it--didn't live up to the hype. A new study published online April 13, 2015, in the journal Nature ...

How oxytocin makes a mom: Hormone teaches maternal brain to respond to offspring's needs

2015-04-15
Neuroscientists at NYU Langone Medical Center have discovered how the powerful brain hormone oxytocin acts on individual brain cells to prompt specific social behaviors - findings that could lead to a better understanding of how oxytocin and other hormones could be used to treat behavioral problems resulting from disease or trauma to the brain. The findings are to be published in the journal Nature online April 15. Until now, researchers say oxytocin -- sometimes called the "pleasure hormone" -- has been better known for its role in inducing sexual attraction and orgasm, ...

Iceberg armadas not the cause of North Atlantic cooling

2015-04-15
Previous studies have suggested that pulses of icebergs may have caused cycles of abrupt climate change during the last glacial period by introducing fresh water to the surface of the ocean and changing ocean currents, which are known to play a dominant role in the climate of many of Earth's regions. However, new findings by scientists at Cardiff University present a contradictory narrative and suggest that icebergs generally arrived too late to trigger marked cooling across the North Atlantic. Abrupt climate change, characterised by transitions between warm and cold ...

Perceptions of environmental damage improves over time, despite lack of real change

2015-04-15
COLUMBIA, Mo. - Invasive pests known as spruce bark beetles have been attacking Alaskan forests for decades, killing more than 1 million acres of forest on the Kenai Peninsula in southern Alaska for more than 25 years. Beyond environmental concerns regarding the millions of dead trees, or "beetle kill" trees, inhabitants of the peninsula and surrounding areas are faced with problems including dangerous falling trees, high wildfire risks, loss of scenic views and increased soil erosion. Now, a researcher from the University of Missouri and his colleagues have found that ...

Brain development suffers from lack of fish oil fatty acids, UCI study finds

2015-04-15
Irvine, Calif., April 15, 2015 -- While recent reports question whether fish oil supplements support heart health, UC Irvine scientists have found that the fatty acids they contain are vitally important to the developing brain. In a study appearing today in The Journal of Neuroscience, UCI neurobiologists report that dietary deficiencies in the type of fatty acids found in fish and other foods can limit brain growth during fetal development and early in life. The findings suggest that women maintain a balanced diet rich in these fatty acids for themselves during pregnancy ...

Man with restored sight provides new insight into how vision develops

2015-04-15
California man Mike May made international headlines in 2000 when his sight was restored by a pioneering stem cell procedure after 40 years of blindness. But a study published three years after the operation found that the then-49-year-old could see colors, motion and some simple two-dimensional shapes, but was incapable of more complex visual processing. Hoping May might eventually regain those visual skills, University of Washington researchers and colleagues retested him a decade later. But in a paper now available online in Psychological Science, they report that ...

New genomic research amends earlier triple negative breast cancer finding

2015-04-15
NEW YORK (April 15, 2015) -- Weill Cornell Medical College investigators tried to validate a previously reported molecular finding on triple negative breast cancer that many hoped would lead to targeted treatments for the aggressive disease. Instead, they discovered that the findings were limited to a single patient and could not be applied to further clinical work. This discovery, published April 15 in Nature, amends the earlier work and underscores the importance of independent study validation and careful assay development. The earlier - and now dispelled - study, ...

Oxycodone overdose deaths drop 25 percent after launch of Prescgram

2015-04-15
GAINESVILLE, Fla. -- Oxycodone-related deaths dropped 25 percent after Florida implemented its Prescription Drug Monitoring Program in late 2011 as part of its response to the state's prescription drug abuse epidemic, according to a team of UF Health researchers. The drop in fatalities could stem from the number of health care providers who used the program's database to monitor controlled substance prescriptions. "Forty-nine states have prescription drug monitoring programs of some kind, but this is the first study to demonstrate that one of these programs significantly ...

LAST 30 PRESS RELEASES:

ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients

New generation of Antibody-Drug Conjugates (ADCs) shows unprecedented promise in early-stage disease

Sylvester Cancer Tip Sheet for October 2025

Three science and technology leaders elected to Hertz Foundation Board of Directors

Jump Trading CSO Kevin Bowers elected to Hertz Foundation Board of Directors

Former Inscripta CEO Sri Kosaraju elected to Hertz Foundation Board of Directors

Citadel’s Jordan Chetty elected to Hertz Foundation Board of Directors

McGill research flags Montreal snow dump, inactive landfills as major methane polluters

A lightweight and rapid bidirectional search algorithm

Eighty-five years of big tree history available in one place for the first time

MIT invents human brain model with six major cell types to enable personalized disease research, drug discovery

Health and economic air quality co-benefits of stringent climate policies

How immune cells deliver their deadly cargo

How the brain becomes a better listener: How focus enhances sound processing

Processed fats found in margarines unlikely to affect heart health

Scientists discover how leukemia cells evade treatment

Sandra Shi MD, MPH, named 2025 STAT Wunderkind

Treating liver disease with microscopic nanoparticles

Chemicals might be hitching a ride on nanoplastics to enter your skin

Pregnant patients with preexisting high cholesterol may have elevated CV risk

UC stroke experts discuss current and future use of AI tools in research and treatment

The Southern Ocean’s low-salinity water locked away CO2 for decades, but...

OHSU researchers develop functional eggs from human skin cells

Most users cannot identify AI bias, even in training data

Hurricane outages: Analysis details the where, and who, of increased future power cuts

Craters on surface of melanoma cells found to serve as sites for tumor killing

Research Spotlight: Mapping overlooked challenges in stroke recovery

Geographic and temporal patterns of screening for breast, cervical, and colorectal cancer in the US

Cannabis laws and opioid use among commercially insured patients with cancer diagnoses

Research Spotlight: Surprising gene mutation in brain’s immune cells linked to increased Alzheimer’s risk

[Press-News.org] Tumor-only genetic sequencing may misguide cancer treatment in nearly half of all patients
Johns Hopkins scientists say the genetic code of tumors must be compared to patients' noncancer genome to get a true picture